Valenzuela C, Snyders D J, Bennett P B, Tamargo J, Hondeghem L M
Institute of Pharmacology and Toxicology, CSIC School of Medicine, Universidad Complutense, Madrid, Spain.
Circulation. 1995 Nov 15;92(10):3014-24. doi: 10.1161/01.cir.92.10.3014.
Bupivacaine is a potent local anesthetic widely used for prolonged local and regional anesthesia. However, accidental intravascular injection of bupivacaine can produce severe arrhythmias and cardiac depression. Although used clinically as a racemic mixture, S(-)-bupivacaine appears less toxic than the R(+)-enantiomer despite at least equal potency for local anesthesia. If the R(+)-enantiomer is more potent in blocking cardiac sodium channels, then the S(-)-enantiomer could be used with less chance of cardiovascular toxicity. Therefore, we tested whether such stereoselectivity existed in the bupivacaine affinity for the cardiac sodium channel.
The inhibitory effects on the cardiac sodium current (INa) of 10 mumol/L R(+)- and S(-)-bupivacaine were investigated by use of the whole-cell voltage clamp technique in isolated guinea pig ventricular myocytes. Both enantiomers produced similar but limited levels of tonic block (6% and 8%). During long depolarizations (5 seconds at 0 mV), R(+)-bupivacaine induced a significantly larger inhibition of INa: 72 +/- 2% versus 58 +/- 3% for the S(-)-enantiomer (P < .01). Development of block was slow, but its rate was faster for R(+)-bupivacaine [time constant, 1.84 +/- 0.16 versus 2.56 +/- 0.26 seconds for the S(-)-enantiomer, P < .05]. The voltage dependence of the availability of the Na+ current was shifted to more hyperpolarizing potentials compared with the control; R(+)-bupivacaine induced a larger shift than S(-)-bupivacaine (37 +/- 2 versus 30 +/- 2 mV, P < .05). These data indicate stereoselective interactions with the inactivated state. In addition, both enantiomers induced substantial use-dependent block during 2.5-Hz pulse trains with medium (100-ms) and short (10-ms) depolarizations but without stereoselective difference. A stepwise approach was used to model these experimental results and to derive apparent affinities and rate constants. We initially assumed that bupivacaine interacted only with the rested and inactivated states of the Na+ channel. The apparent affinities of the inactivated state for S(-)- and R(+)-bupivacaine were 4.8 and 2.9 mumol/L, respectively. With the derived binding and unbinding rate constants, this model reproduced the stereoselective block during long depolarizations but failed to predict the use-dependent block induced by trains of short (10-ms) depolarizations. To account for the observed use-dependent interactions, it was necessary to include interactions with the activated state, which resulted in adequate reproduction of the experimental results. The apparent affinities of the activated or open state for S(-)- and R(+)-bupivacaine were 4.3 and 3.3 mumol/L, respectively.
Both the large level of pulse-dependent block and the failure of the pure inactivated-state block model indicate that bupivacaine interacts with the activated (or open) state of the cardiac sodium channel in addition to its block of the inactivated state. The bupivacaine-induced block of the inactivated state of the Na+ channel displayed stereoselectivity, with R(+)-bupivacaine interacting faster and more potently. Both enantiomers also bind with high affinity to the activated or open state of the channel, but this interaction did not display stereoselectivity, although the binding to the activated or open state was faster for S(-)- than for R(+)-bupivacaine. The higher potency of R(+)-bupivacaine to block the inactivated state of the cardiac Na+ channel may explain its higher toxicity because of the large contribution of the inactivated-state block during the plateau phase of the cardiac action potential. These results would support the use of the S(-)-enantiomer to reduce cardiac toxicity.
布比卡因是一种强效局部麻醉药,广泛用于延长局部及区域麻醉。然而,意外血管内注射布比卡因可导致严重心律失常及心脏抑制。尽管临床上使用的是消旋混合物,但S(-)-布比卡因的毒性似乎低于R(+)-对映体,尽管其局部麻醉效力至少相当。如果R(+)-对映体在阻断心脏钠通道方面更有效,那么使用S(-)-对映体时发生心血管毒性的可能性可能较小。因此,我们测试了布比卡因对心脏钠通道的亲和力是否存在这种立体选择性。
采用全细胞膜片钳技术,在分离的豚鼠心室肌细胞中研究了10 μmol/L R(+)-和S(-)-布比卡因对心脏钠电流(INa)的抑制作用。两种对映体产生的持续性阻滞水平相似但有限(分别为6%和8%)。在长时间去极化(0 mV下5秒)期间,R(+)-布比卡因对INa的抑制作用明显更大:分别为72±2%和58±3%(S(-)-对映体,P <.01)。阻滞的发展较慢,但R(+)-布比卡因的速率更快[时间常数,S(-)-对映体为1.84±0.16秒,R(+)-布比卡因为2.56±0.26秒,P <.05]。与对照组相比,钠电流可用性的电压依赖性向更超极化的电位偏移;R(+)-布比卡因引起的偏移比S(-)-布比卡因更大(37±2 mV对30±2 mV,P <.05)。这些数据表明与失活状态存在立体选择性相互作用。此外,在2.5 Hz脉冲串期间,两种对映体在中等(100 ms)和短(10 ms)去极化时均诱导出显著程度的使用依赖性阻滞,但无立体选择性差异。采用逐步方法对这些实验结果进行建模,并得出表观亲和力和速率常数。我们最初假设布比卡因仅与钠通道的静息和失活状态相互作用。S(-)-和R(+)-布比卡因对失活状态的表观亲和力分别为4.8和2.9 μmol/L。利用推导的结合和解离速率常数,该模型再现了长时间去极化期间的立体选择性阻滞,但未能预测短(10 ms)去极化脉冲串诱导的使用依赖性阻滞。为了解释观察到的使用依赖性相互作用,有必要纳入与激活状态的相互作用,这导致实验结果得到充分再现。S(-)-和R(+)-布比卡因对激活或开放状态的表观亲和力分别为4.3和3.3 μmol/L。
高水平的脉冲依赖性阻滞以及纯失活状态阻滞模型的失败均表明,布比卡因除了阻断失活状态外,还与心脏钠通道的激活(或开放)状态相互作用。布比卡因诱导的钠通道失活状态阻滞表现出立体选择性,R(+)-布比卡因的相互作用更快且更强效。两种对映体也以高亲和力与通道的激活或开放状态结合,但这种相互作用未表现出立体选择性,尽管S(-)-布比卡因与激活或开放状态的结合比R(+)-布比卡因更快。R(+)-布比卡因阻断心脏钠通道失活状态的效力更高,这可能解释了其更高的毒性,因为在心脏动作电位的平台期,失活状态阻滞起了很大作用。这些结果支持使用S(-)-对映体来降低心脏毒性。